Login / Signup

FungiScope™ -Global Emerging Fungal Infection Registry.

Danila SeidelLuisa A Durán GraeffMaria J G T VehreschildHilmar WisplinghoffMaren ZieglerJörg Janne VehreschildBlasius Janusch LissAxel G HamprechtPhilipp KöhlerZdenek RacilNikolai N KlimkoDonald C SheppardRaoul HerbrechtAnuradha ChowdharyOliver Andreas Cornelynull FungiScope Group
Published in: Mycoses (2018)
Rare invasive fungal diseases (IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late onset of treatment and inappropriate medication is associated with high mortality, thus, urging the need for a better understanding of these diseases. The purpose of FungiScope™ is to continuously collect clinical information and specimens to improve the knowledge on epidemiology and eventually improve patient management of these orphan diseases. FungiScope™ was founded in 2003, and today, collaborators from 66 countries support the registry. So far, clinical data of 794 cases have been entered using a web-based approach. Within the growing network of experts, new collaborations developed, leading to several publications of comprehensive analyses of patient subgroups identified from the registry. Data extracted from FungiScope™ have also been used as the sole control group for the approval of a new antifungal drug. Due to the rarity of these diseases, a global registry is an appropriate method of pooling the scarce and scattered information. Joining efforts across medical specialities and geographical borders is key for researching rare IFD. Here, we describe the structure and management of the FungiScope™ registry.
Keyphrases
  • late onset
  • healthcare
  • primary care
  • case report
  • early onset
  • risk factors
  • emergency department
  • cardiovascular disease
  • dna repair
  • adverse drug
  • social media
  • candida albicans